A New Peptide Input to Learning and Addiction
In this issue of Neuron, Borgland et al. report that the arousal-associated peptide orexin enhances LTP-like changes in glutamatergic excitability of ventral tegmental dopamine neurons. This parallels a similar effect of corticotropin-releasing factor and suggests a form of neuroadaptation that increases the likelihood of addiction relapse.
Borgland and colleagues (Borgland et al., 2006) report that orexin A input to the ventral tegmental area (VTA) (1) potentiates, by a PKC/PLC pathway, NMDA receptor-mediated excitatory postsynaptic currents in dopamine neurons; (2) modulates NMDA receptor composition; (3) translocates NMDA receptors to the synapse; (4) causes AMPA receptor-mediated synaptic plasticity; (5) facilitates cocaine-induced potentiation of excitatory input to VTA dopamine neurons; and (6) plays a critical role in cocaine-induced psychomotor sensitization. These findings parallel similar findings with CRF, made earlier by the Bonci group (Ungless et al., 2003) . The two findings link potential mechanisms of learning and memory to mechanisms of addiction, adding an important dimension to addiction research.
It is widely suspected that drug-induced neuroadaptations (and not just those of the simple memory trace for the drug experience) differentiate the addicted from the nonaddicted brain. While eating and sexual habits can become compulsive to the point of risk for diabetes, cardiovascular disease, or loss of public office, addiction is seen to involve even more compulsive habits and to require even stronger explanations and more complex mechanisms. From this perspective, it is not enough that addictive drugs activate brain reward circuitry more strongly or more immediately; rather, addictive drugs are seen to alter the brain in ways that make the drug more habit-forming than ''natural'' rewards and more habit-forming for the addict than for the nonaddict. Addictive drugs do, of course, alter the brain, and many of the alterations are long-lasting.
The findings of the Bonci group advance the field of addiction research in three ways. First, rather than a mechanism primarily involved in pharmacological responses to ingested cocaine, they have identified a neuroadaptation (sensitization of mesolimbic dopaminergic neurons to glutamatergic input) that links drug reward circuitry to the arousal messenger orexin and, in earlier studies (Ungless et al., 2003) , to the stress messenger corticotropin-releasing factor (CRF). Stress and arousal are phenomena that can trigger drug-seeking in abstinent subjects (Shalev et al., 2002) ; they can get drugseeking started and not just maintain it once it is under way. Here we have clues, perhaps, as to how early experience can predispose some individuals to addiction by sensitizing the brain to emotional events.
Second, these studies begin to bring peptide neurotransmitters into the discussion of neuroplasticity in addiction. While opioid peptide neurotransmitters have long been studied because they act at the same receptors as addictive opiates, studies of neuroadaptations to drugs of abuse have focused largely on the ''primary'' neurotransmitters dopamine, glutamate, and GABA.
Third, these studies take an important step toward relating the neuroadaptations of addiction to mechanisms associated with the cellular basis of learning and memory (see Kelley, 2004) . Orexin in the new study and CRF in the earlier work each modulate glutamatergic activation of midbrain dopamine neurons in much the same way as is seen in long-term potentiation. The very similar characteristics of orexin-induced and CRF-induced sensitization of the activation of dopaminergic neurons by glutamate suggest a common or at least strongly overlapping mechanism. Changes in synaptic efficacy such as those induced by orexin and CRF are not only likely to underlie learned stress and arousal responses to the environment, they are also likely, perhaps in other parts of the brain, to help consolidate the specific memories (the ''remembered high'') associated with the drug experience.
Intraventricular (Boutrel et al., 2005) or VTA (Harris et al., 2005) infusions of orexin are known to reinstate drug-seeking in rodents, as do intraventricular (Shaham et al., 1997) or VTA (Wang et al., 2005) infusions of CRF. Ventral tegmental injections of an orexin antagonist block the development of heroin-conditioned place preferences (Narita et al., 2006) . Inasmuch as arousal or stress can trigger drug-seeking in drug-free animals, the neuroadaptations discovered by the Bonci group are important not only for how rewarding the drug is after an animal starts taking it, but, perhaps more importantly, for how likely the animal is to initiate drug-seeking during periods of abstinence. Because it is during periods of abstinence, not periods of intoxication, that addicts seek treatment, the peptide signaling pathways for orexin and CRF may prove to be fruitful targets in the search for addiction medications. 
Dopamine Receptor Excess and Mouse Madness
The dopamine hypothesis of schizophrenia is based on evidence that the major antipsychotic drugs act by blocking dopamine D2 receptors and that dopamine-releasing drugs worsen symptoms. In this issue of Neuron, Kellendonk et al. report an elegant conditional transgenic mouse overexpressing dopamine D2 receptors selectively in the striatum. Strikingly, these animals display selective cognitive impairment typically associated with frontal cortical defects and abnormal dopamine markers in the prefrontal cortex, suggesting that striatal dopamine receptors can influence cortical dopamine function.
The dopamine hypothesis of schizophrenia derives from a concatenation of diverse evidence (Snyder, 1976) . The initial, most compelling findings were pharmacologic. In 1963, Arvid Carlsson observed changes in levels of dopamine metabolites in rats treated with antipsychotic neuroleptic drugs and speculated that these may reflect augmented firing of dopamine neurons secondary to blockade of receptors. The ability to monitor dopamine receptors by ligand binding permitted the discovery of very potent and selective blockade of dopamine D2 receptors by neuroleptic drugs with molecular potencies paralleling therapeutic potencies. Amphetamine, which releases dopamine, selectively exacerbates schizophrenic symptoms.
Patricia Goldman-Rakic (Goldman-Rakic, 1999) established a role for the dopamine neurons that project to the prefrontal cerebral cortex in regulating cognitive functions that are selectively impaired in schizophrenics. Dopamine projections to the prefrontal cortex arise from the ventral tegmental area of the midbrain. The most prominent dopamine pathway has cell bodies in the substantia nigra with axons projecting to the caudate and putamen collectively called the striatum. Degeneration of this pathway gives rise to the symptoms of Parkinson's disease so that the striatum has generally been assigned a primary role in regulating motor behavior. However, the striatum can influence the cerebral cortex via projections to the pallidum, thence to the thalamus, and onward to the cortex. Dopamine might modulate schizophrenic behavior without being fundamental to the disease's pathophysiology. A direct link comes from studies reporting increased numbers of dopamine D2 receptors in the striatum of schizophrenic brain (Seeman and Kapur, 2000) . However, prolonged treatment with neuroleptics leads to augmented numbers of D2 receptors, and there are few drug-naive schizophrenics.
If hyperactivity of dopamine systems mediated by augmented numbers of D2 receptors underlies schizophrenic dysfunction, then a transgenic mouse overexpressing D2 receptors might provide an animal model of schizophrenia. In this issue of Neuron, Kellendonk et al. (2006) have aimed to create such a model by creating D2 receptor transgenic mice. Most elegant about this system is that the transgene is conditional, being under the control of a tetracycline response element that can be turned off by oral administration of the antibiotic doxycycline. Additionally, the transgene is selectively expressed in the striatum and not in other areas of the brain that possess D2 receptors. The striatum of the transgenic mice displays increased numbers of D2 receptor binding sites and increased effects on adenylyl cyclase indicating that the transgenic receptors are functional. Overall behavior of the mutant mice is normal with unaltered locomotor activity, sensorimotor gating, and generalized anxiety. However, the mice display substantial defects in working memory tasks and behavioral flexibility typically associated with prefrontal cortical function. The authors provide direct evidence that the striatal D2 receptors somehow influence the cortex because the mutant mice display altered glucose metabolism, dopamine levels, and dopamine D1 receptor activation in the prefrontal cortex. Reversal of the transgene with doxycycline treatment does not reverse the cognitive defects, indicating that the behavioral deficit presumably reflects D2 receptor overexpression during fetal life.
The Kellendonk study clearly establishes an influence of striatal D2 receptors upon biochemical markers and cognitive behaviors associated with the prefrontal cortex. Do these findings teach us about the pathophysiology of schizophrenia? Do these mice provide an animal model of schizophrenia? Recent genetic studies afford a basis for optimism. Numerous workers have had some success in identifying specific genes linked to schizophrenia. Best characterized is DISC1, a cytoskeletal protein that binds to a subtype of phosphodiesterase and inhibits its catalytic activity (Millar et al., 2005) . Because this phosphodiesterase metabolizes cyclic AMP, which is a second messenger for dopamine, one might speculate about some relationship. Weinberger and colleagues (Winterer and Weinberger, 2004) provided evidence that polymorphisms in catechol-O-methyltransferase (COMT) impact dopamine transmission in prefrontal cortex, prefrontal-linked cognitive behavior, and schizophrenic behavior. Thus, it is not at all farfetched to envisage dopamine disturbances eliciting schizophrenic mental aberrations. In this case, the transgenic mice developed by Kellendonk and colleagues
